About the Journal

​​​​​​Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool. 

Publication & Editorial Staff Contacts

Senior Publisher Phil Daly [email protected] Production Editor Asha Ladwa [email protected]​wolterskluwer.com ​​Marketing Brian Freiland [email protected]​ Advertising For journal specific contacts go to media kit site Permissions Go to the article and use the Content & Permissions link under Article Tools Translations Rights & Licensing [email protected] [email protected] Reprints and Special Projects (U.S./Canada) For journal specific contacts go to media kit site​ Reprints and Special Projects (non-U.S./Canada) [email protected] and for journal specific contacts go to media kit site​ Supplements Phil Daly, Publisher Phone: +44 203 197 6676 E-mail: [email protected] ​LWW Business Offices Citi Building, 41st Floor 25 Canada Square Canary Wharf London E14 5LQ United Kingdom Tel: +44 (0)20 3197 6500 Fax: +44 (0)20 3197 6501 www.lww.com

​Editor-in-Chief Professor Paul Dent Department of Biochemistry Virginia Commonwealth University VCU Massey Cancer Center 401 College Street Richmond VA 23298-0035 USA [email protected]​